Comparative study of efficacy of topical anthralin (0.5%) and topical calcipotriol (0.005%) in management of chronic plaque psoriasis
Keywords:
Calcipotriol, Anthraline, Psoriasis, EfficacyAbstract
Objective The aim of the study is to compare the efficacy of topical calcipotriol (0.005%) and topical anthralin (0.5%) in treatment of Chronic Plaque Psoriasis (CPP). Methods This randomized, interventional study was conducted at Pak Emirates Military Hospital, Rawalpindi and Combined Military Hospital, Rawalpindi for 6-month period (10th January 2020 to 10th July 2020). A sample of 186 patients was randomly distributed in two groups. In group A, patients applied topical anthralin (0.5%) every night for 12 weeks. In group B, patients applied topical calcipotriol (0.005%) every night for 12 weeks. The follow up period was 12 weeks and assessment of the efficacy was done at 4, 8 and 12 weeks by utilizing PASI score. Results The age range of the individuals was from 15 to 50 years. The average duration of presenting complaint for Group A was 8.903±1.85 months while for Group B was 9.193±2.58 months. In Group A, the average PASI score before and after the treatment was 16.22±3.02 and 4.784±3.28 respectively and in Group B the average PASI score before and after the treatment was 16.03±2.09 and 2.376±2.39 respectively. The number of male patients in each group was more than female. Efficacy i.e. reduction in PASI score by 75% was seen in 21.5% patients of Group A as compared to 43% in Group B (p=0.001). Conclusion In conclusion, 0.005% calcipotriol is considerably more efficacious than 0.5% anthraline in bringing disease improvement and patient satisfaction than 0.5% anthraline.References
Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945-60.
Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, et al. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1. J Am Acad Dermatol. 2020;83(6):1704-16.
Knuckles ML, Levi E, Soung J. Defining and treating moderate plaque psoriasis: a dermatologist survey. J Dermatol Treat. 2018;29(7):658-63.
Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117-22.
Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, et al. From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290-8.
Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97-109.
Samarasekera E, Sawyer L, Wonderling D, Tucker R, Smith C. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta‐analyses. Br J Dermatol. 2013;168(5):954-67.
Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, et al. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774-90.
Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8(4):235.
Tripathi P, Bhardwaj P. Psoriasis: An autoimmune disorder. J Drug Deliv Ther. 2020;10(5):316-24.
Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013;(3):CD005028.
Nast A, Smith C, Spuls P, Avila Valle G, Bata‐Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461-98.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. International journal of molecular sciences. 2019;20(6):1475.
Sbidian E, Chaimani A, Afach S, Doney L, Dressler C, Hua C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535.
Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet. 2019;394(10198):576-86.
Cameron JB, Van Voorhees AS. Introduction to and History of Psoriasis and Psoriasis Therapy. Advances in Psoriasis: Springer; 2021. p. 1-7.
Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432-70.
Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97.
Ring J. The history of dermatology helps to understand debates of today. Wiley Online Library; 2018. p. 1053-.
Ricceri F, Bardazzi F, Chiricozzi A, Dapavo P, Ferrara F, Mugheddu C, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33(1):143-6.
